Literature DB >> 19911114

Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain.

Tiago P Freitas1, Giselli Scaini, Cristiane Corrêa, Patricia M Santos, Gabriela K Ferreira, Gislaine T Rezin, Morgana Moretti, Samira S Valvassori, João Quevedo, Emilio L Streck.   

Abstract

Bipolar disorder (BD) is a common and severe mood disorder associated with higher rates of suicide and disability. The development of new animal models, and the investigation employing those available have extensively contributed to understand the pathophysiological mechanisms of BD. Intracerebroventricular (i.c.v.) administration of ouabain, a specific Na+,K+-ATPase inhibitor, has been used as an animal model for BD. It has been demonstrated that Na+,K+-ATPase is altered in psychiatric disorders, especially BD. Creatine kinase (CK) is important for brain energy homeostasis by exerting several integrated functions. In the present study,we evaluated CK activity in the striatum, prefrontal cortex and hippocampus of rats subjected to i.c.v. administration of ouabain. Adult male Wistar rats received a single i.c.v. administration of ouabain (10(-2) and 10(-3) M) or vehicle (control group). Locomotor activity was measured using the open field test. CK activity was measured in the brain of rats immediately (1 h) and 7 days after ouabain administration. Our results showed that spontaneous locomotion was increased 1 h after ouabain administration and that hyperlocomotion was also observed 7 days after that.Moreover, CK activity was inhibited immediately after the administration of ouabain in the striatum, hippocampus and prefrontal cortex. Moreover, the enzyme was not affected in the striatum and hippocampus 7 days after ouabain administration. On the other hand, an inhibition in CK activity in the prefrontal cortex was observed. If inhibition of CK also occurs in BD patients, it will be tempting to speculate that the reduction of brain metabolism may be related probably to the pathophysiology of this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19911114     DOI: 10.1007/s00702-009-0337-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  41 in total

1.  Octamers of mitochondrial creatine kinase isoenzymes differ in stability and membrane binding.

Authors:  U Schlattner; T Wallimann
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

2.  Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness.

Authors:  S Decker; G Grider; M Cobb; X P Li; M O Huff; R S El-Mallakh; R S Levy
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2000-04       Impact factor: 5.067

3.  A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera.

Authors:  B P HUGHES
Journal:  Clin Chim Acta       Date:  1962-09       Impact factor: 3.786

Review 4.  The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings.

Authors:  S M Strakowski; M P Delbello; C M Adler
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

5.  The increasing medical burden in bipolar disorder.

Authors:  David J Kupfer
Journal:  JAMA       Date:  2005-05-25       Impact factor: 56.272

Review 6.  Mitochondrial dysfunction in bipolar disorder.

Authors:  T Kato; N Kato
Journal:  Bipolar Disord       Date:  2000-09       Impact factor: 6.744

7.  The role of the extracellular signal-regulated kinase signaling pathway in mood modulation.

Authors:  Haim Einat; Peixiong Yuan; Todd D Gould; Jianling Li; JianHua Du; Lei Zhang; Husseini K Manji; Guang Chen
Journal:  J Neurosci       Date:  2003-08-13       Impact factor: 6.167

8.  Molecular evidence for mitochondrial dysfunction in bipolar disorder.

Authors:  Christine Konradi; Molly Eaton; Matthew L MacDonald; John Walsh; Francine M Benes; Stephan Heckers
Journal:  Arch Gen Psychiatry       Date:  2004-03

9.  Brain metabolic alterations in medication-free patients with bipolar disorder.

Authors:  Stephen R Dager; Seth D Friedman; Aimee Parow; Christina Demopulos; Andrew L Stoll; In Kyoon Lyoo; David L Dunner; Perry F Renshaw
Journal:  Arch Gen Psychiatry       Date:  2004-05

10.  Decreased temporal lobe phosphomonoesters in bipolar disorder.

Authors:  R F Deicken; M W Weiner; G Fein
Journal:  J Affect Disord       Date:  1995-03-14       Impact factor: 4.839

View more
  5 in total

Review 1.  Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?

Authors:  Patricia J Allen
Journal:  Neurosci Biobehav Rev       Date:  2012-03-24       Impact factor: 8.989

Review 2.  Impaired mitochondrial function in psychiatric disorders.

Authors:  Husseini Manji; Tadafumi Kato; Nicholas A Di Prospero; Seth Ness; M Flint Beal; Michael Krams; Guang Chen
Journal:  Nat Rev Neurosci       Date:  2012-04-18       Impact factor: 34.870

3.  Effect of physical exercise on changes in activities of creatine kinase, cytochrome c oxidase and ATP levels caused by ovariectomy.

Authors:  Cassiana Siebert; Janaína Kolling; Emilene B S Scherer; Felipe Schmitz; Maira Jaqueline da Cunha; Vanize Mackedanz; Rodrigo B de Andrade; Clovis M D Wannmacher; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2014-05-10       Impact factor: 3.584

4.  Intracerebroventricular administration of ouabain alters synaptic plasticity and dopamine release in rat medial prefrontal cortex.

Authors:  Li Sui; Xiao-Jin Song; Jie Ren; Li-Hua Ju; Yan Wang
Journal:  J Neural Transm (Vienna)       Date:  2013-01-12       Impact factor: 3.575

5.  A rodent model of schizophrenia reveals increase in creatine kinase activity with associated behavior changes.

Authors:  Leila Canever; Larissa Oliveira; Renata D'Altoé de Luca; Paulo T F Correa; Daiane de B Fraga; Maria Paula Matos; Giselli Scaini; João Quevedo; Emílio L Streck; Alexandra I Zugno
Journal:  Oxid Med Cell Longev       Date:  2010-11-01       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.